In VivoBiopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede
In VivoDemand for certain types of medtech, industrial operations, supply chains and distribution systems were all impacted to some extent by COVID-19 in 2020. So were product development milestones, clinica
Medtech InsightThe latest Medtech Insight sales ranking of the top 100 publicly-traded medtech manufacturers is COVID-19-affected for a relatively sizeable proportion of companies ̶ those whose reporting perio